Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae and Haemophilus influenzae with the use of Monte Carlo simulation

Japanese Journal of Antibiotics

Volumn 59, Issue 6, 2006, Pages 468-473

  Mikamo, Hiroshige ^a,b   Tanaka, Kaori ^a   Watanabe, Kunitomo ^a  

^a GIFU UNIVERSITY   (Japan)

^b GIFU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; TOSUFLOXACIN;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; STREPTOCOCCUS PNEUMONIAE;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MONTE CARLO METHOD; NAPHTHYRIDINES; NITROFURANS; OXAZOLIDINONES; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 33846817475     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Japanese source
2. Japanese source
3. CRAIG, W. A.: Pharmacokinetic/Pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clinical Infectious Disease 26: 1-12, 1998
4. Jpn. J. Antibiotics 58: 159-167, 2005
5. Jpn. J. Antibiotics 58: 359-367, 2005
6. KUTI, J. L.; P. DANDEKAR, C. H. NIGHTINGALE & D. P. NICOLAU: Use of monte carlo simulation to design anoptimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol. 43: 1116-1123, 2003
7. KUTI, J. L; C. H. NIGHTINGALE & D. P. NICOLAU: Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in north America in 2002. Antimicro. Agents Chemoth. 48: 2464-2470, 2004
8. Jpn. J. Antibiotics 57: 172-185, 2004
9. Jpn. J. Antibiotics 58: 290-301, 2005
10. TANIGAWARA, Y.; H. NOMURA, N. KAGIMOTO, et al.: Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. Biol. Pharm. Bull. 18: 315-320 1995
11. Chemotherapy 36(S-9): 158-180, 1988
12. Chemotherapy 36(S-9): 408-412, 1988
13. Chemotherapy 36(S-9): 943-966, 1988
14. Chemotherapy 36(S-9): 1129-1138, 1988
15. Chemotherapy 36(S-9): 1488-1507, 1988
16. CRAIG, W. A.: The role of pharmacodynamics infective treatment of community - acquired pathogens. Advanced Studies in Med. 2: 126-134, 2002
17. MASTERTON, R. G.; J. L. KUTI, P. J. TURNER, et al.: The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J. Antimicrob. Chemother. 55: 71-77, 2005
18. Japanese source